News & Media

Explore what’s happening here

Sumitomo Dainippon Pharma Oncology (SDP Oncology) is advancing innovative science and transforming new discoveries into meaningful therapeutic options for patients with cancer. To learn more about our most recent discoveries, commercial efforts, and cancer care projects, see our press releases and other news below.

To contact our media relations staff, click here.

Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Alvocidib at 62nd ASH Annual Meeting
11/06/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data from the Phase 2 Zella 201 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, will be presented at the 62nd American Society of Hematology Annual Meeting, being held virtually December 5-8, 2020. Zella 201 is a biomarker-driven study of alvocidib followed by cytarabine and mitoxantrone in patients with relapsed/refractory MCL-1 dependent acute myeloid leukemia (AML). Data presented will include findings from an exploratory cohort of newly diagnosed, high-risk patients with MCL-1 dependent AML.

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 2 Dose-Expansion Portion of Study Evaluating Investigational WT1 Immunotherapeutic Cancer Vaccine DSP-7888 (ombipepimut-S*) in Patients with Ovarian Cancer
10/27/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in the Phase 2 expansion portion of the study evaluating DSP-7888, an investigational immunotherapeutic cancer vaccine that targets Wilms Tumor 1 (WT1), in combination with checkpoint inhibitor pembrolizumab, in patients with platinum-resistant ovarian cancer (PROC).

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
10/23/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1b/2 study evaluating the oral investigational agent, dubermatinib (TP-0903), an AXL kinase inhibitor, in combination with decitabine, in patients 60 years or older with newly diagnosed acute myeloid leukemia (AML) who have TP53 mutations and/or complex karyotype. This study is a new arm included in The Leukemia & Lymphoma Society's (LLS) groundbreaking Beat AML Master Clinical Trial.

Read more

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed with TP-1454 in Patients with Advanced Solid Tumors
10/09/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed with TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, administered alone and in combination with ipilimumab and nivolumab, in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors.

Read more

Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress
09/18/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903), an AXL kinase inhibitor, in patients with advanced solid tumors. These results were presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19-21, 2020.

Read more

The Alliance and TrialJectory report on collaboration to improve access to advanced cancer treatment
09/14/2020

Colorectal Cancer Alliance

Read more

Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Dubermatinib at ESMO 2020 Virtual Annual Congress
09/11/2020

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that new data evaluating the oral investigational agent dubermatinib (TP-0903), an AXL kinase inhibitor, will be presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Congress, being held September 19-21, 2020. Data will be shared during the Developmental Therapeutics Mini-Oral Presentation and include findings from a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics and clinical activity of dubermatinib in patients with advanced solid tumors.

Read more

Japan’s Sumitomo merges oncology arms Tolero Pharma, Boston Biomedical
07/03/2020

Leslie Shaffer / Deal Street Asia

Read more

An experienced biotech is stitched together from transpacific parts, with 265 staffers and a focus on ‘new biology’
07/01/2020

John Carroll / Endpoints News

Read more

Sumitomo merges U.S. biotechs to create oncology division
07/01/2020

Nick Paul Taylor / FierceBiotech

Read more

Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
07/01/2020

Sumitomo Dainippon Pharma Oncology Advances Meaningful Therapies for Cancer Patients through Innovative Drug Discovery, Research and Development.

Read more

Disclaimer

By clicking on a link on this page, you may exit the SDP Oncology website for a third party website. Links which take you out of the SDP Oncology website are not under the control of SDP Oncology, and SDP Oncology is not responsible for the contents of any such site or any further links from such site. SDP Oncology is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by SDP Oncology. The website that you have requested also may not be optimized for your screen size.